Citizens analyst Silvan Tuerkcan raised the firm’s price target on Relay Therapeutics (RLAY) to $19 from $17 and keeps an Outperform rating on the shares. Relay’s triplet regimen has shown encouraging early efficacy and tolerability in the frontline endocrine-sensitive setting, with the inclusion of atirmociclib potentially offering a competitive edge, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Analyst Reiterates Buy on Relay Therapeutics, Citing Promising Zovega mBC Data, Favorable Safety Profile, and Phase 3 First-Line Breast Cancer Upside
- Relay Therapeutics advances zovegalisib combo in breast cancer
- Relay Therapeutics’ combination for breast cancer shows efficacy and safetyPfizer
- Relay Therapeutics initiated with a Hold at JonesResearch
- Relay Therapeutics price target raised to $21 from $17 at Barclays